Compare Koninklijke Philips NV (PHG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Revvity Inc — how do they compare? Koninklijke Philips NV trades at $24.14 (market cap $23.52B), while Revvity Inc trades at $154.78 (market cap $16.98B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Revvity Inc for 12 Days on average.
| PHG | RVTY | |
|---|---|---|
Market Cap | $23.52B | $16.98B |
Volume | 1,635,069 | 1,456,900 |
Sector | Health | Health |
52-Week High | $32.91 | $157.36 |
52-Week Low | $23.81 | $82.26 |
Typical Hold Time | 84 Days | 12 Days |
Enterprise Value | $29.87B | $19.30B |
Dividend Yield | 4.17% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
